m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG00048)
Name |
AS-601245
|
||||
---|---|---|---|---|---|
Synonyms |
JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673
Click to Show/Hide
|
||||
Status |
Investigative
|
||||
Structure |
|
||||
Formula |
C20H16N6S
|
||||
InChI |
1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,15H,7,10H2,(H,23,24,26)
|
||||
InChIKey |
RCYPVQCPYKNSTG-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glycogen synthase kinase-3 beta (GSK-3B)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AS-601245. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AS-601245 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [1], [2] | ||
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for AS-601245. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AS-601245 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). | [2], [3] | ||
Stress-activated protein kinase JNK1 (JNK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for AS-601245. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AS-601245 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [4], [5] | ||
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for AS-601245. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AS-601245 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [5], [6] | ||
References